Amgen Inc. $AMGN Stock Sold by Kestra Investment Management LLC

Kestra Investment Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 23.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,160 shares of the medical research company’s stock after selling 1,548 shares during the period. Kestra Investment Management LLC’s holdings in Amgen were worth $2,175,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp raised its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. MW Advisory LLC bought a new stake in Amgen in the second quarter valued at $1,054,000. Baird Financial Group Inc. boosted its holdings in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Amgen by 105.8% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after purchasing an additional 6,947 shares during the period. Finally, Nilsine Partners LLC purchased a new position in Amgen during the 2nd quarter valued at $3,329,000. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

AMGN has been the subject of several research reports. Royal Bank Of Canada upped their price objective on shares of Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Morgan Stanley lifted their target price on shares of Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Wednesday, November 4th. Robert W. Baird increased their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, Oppenheimer restated an “outperform” rating on shares of Amgen in a report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $422.76.

Amgen Price Performance

AMGN opened at $465.23 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The company has a market cap of $251.65 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. The stock has a fifty day simple moving average of $423.79 and a two-hundred day simple moving average of $379.39. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.64 EPS. Research analysts predict that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 58.47%.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.